Trademarks are an important part of an enterprise's intangible assets and comprehensive competitiveness. At present, Deepblue Medical's Chinese, English and graphic trademarks have all applied for registration protection, effectively protecting the company's intangible assets and legitimate rights and interests. Over the years, the company has continued to explore the international market, and the number of countries and regions for product export has continued to increase. In order to further protect the company’s rights and interests in the international market, the company has continued to expand its brand influence and market share. In 2020, Deepblue Medical carried out trademark protection in various countries through the Madrid trademark system, and successively received approval and protection. On December 15, DEEPBLUE obtained the approval protection notice from the Slovak State. The successful acquisition of Slovakia’s approval and protection this time is an important step and result of Deepblue Medical’s establishment of a global brand. It is also a strong guarantee for the protection of the exclusive rights of Deepblue Medical’s overseas trademarks. It is a milestone for Deepblue’s future development and is a brand competition for Deepblue. It has laid a solid foundation for achieving innovation-driven, boosting the development of foreign markets, creating high-quality brands, and achieving higher-level development.

Since November this year, the new crown Omicon strain (B.1.1.529) has "appeared" in more than 77 countries and regions. The WHO said that Omicron is spreading at an unprecedented speed. The mutant strain of the COVID-19 "Omicron" has been discovered in many countries. Many people are worried about whether the existing detection reagents for the mutant strain can be effectively detected? Recently, Anhui Deepblue Medical Technology Co., Ltd. (hereinafter referred to as "Deepblue Medical") announced that existing reagents can effectively detect Omicon mutant strains. According to relevant evidence, the transmission capacity of "Omicron" is 3-4 times that of the previous "Delta". Some scholars have pointed out that "Omicron" may be more terrifying than all previous mutants. This mutant strain carries more than 50 mutations in total, and is the most mutated COVID-19 so far. Among them, there are as many as 32 S protein mutations, while Delta only has 16 S protein mutations. Therefore, the strain can avoid the immune system more effectively, so it has a higher transmission capacity. This new strain with extremely strong transmission capacity will pose a great challenge to the epidemic prevention work of all countries in the world. Therefore, the rapid and accurate realization of the The detection of the virus is an urgent technical problem that needs to be broken through in various countries. As early as the beginning of 2020, Deepblue Medical began research on the sudden new crown virus and responded quickly. Its products have successively passed the British Phase 3B test, the special authorization of BfarM in Germany, etc., and have been included in the white list of French new crown reagent exports and obtained CE certification. At the same time, 10,000 SARS-CoV-2 (IgG/IgM) antibody detection reagents were donated to King's College London through the HSBC Business School of Peking University, which was also highly recognized by King's College London. In response to the needs of rapid detection of new coronavirus and home detection, Deepblue's early independent research and development of new coronavirus detection product layout covers antibody, antigen, and neutralizing antibody detection kits, which can complete rapid sample detection in 15 minutes and at the same time have high sensitivity, which can meet the needs of hospitals and institutions. And home self-test needs. In response to the latest developments of the virus mutant strain Omicron, Deepblue Medical immediately carried out computer simulation verification of all reported N protein mutation sequences and the target sequences we detected. The results confirmed that all N protein mutation sites are not in our target detection area. Therefore, Omicron’s N protein mutation will not affect the performance of Deepblue COVID-19 (SARS-CoV-2) antigen detection reagent, indicating that Deepblue medical new crown There will be no off-target and missed detection of the antigen detection r...

Since the outbreak of the novel coronavirus epidemic, the global epidemic prevention and control situation has never slackened. The vaccination rate of the novel coronavirus has been continuously increased, which has effectively controlled the global epidemic. However, the rapid iteration and spread of the mutant strain of the novel coronavirus has recently spread to more than 20 countries, and the global epidemic prevention and control is once again facing a severe test. In this environment, popularizing the convenient and efficient rapid detection of the epidemic has become the top priority of the European epidemic prevention and control work. On August 17th, the novel coronavirus antigen detection reagent independently developed and produced by Anhui Deepblue Medical successfully obtained the Italian family self-test certificate and the Portuguese family self-test certificate, which undoubtedly brought a more convenient and efficient testing experience and improved European epidemic prevention and control. Sufficient testing resources. Deepblue novel coronavirus(COVID-19) home self-testing antigen detection reagent successfully obtained the Italian home self-testing certificate, which means that the product will be widely used in Italy, speed up the anti-epidemic process of the global compatriots, and lead the innovative development of the global COVID-19 antigen test suitable for home self-testing, avoiding Long queues in medical institutions bring the risk of mutual infection. The picture above shows the Italian self-test registration certificate On August 19, another piece of good news came that the Deepblue COVID-19 Home Self-Assessment Antigen Detection Reagent was certified in Portugal, which means that the promotion of Deepblue products in the international market has once again added a strong pass to enterprises. The new leap of international business has important strategic significance. The picture above shows the Portuguese self-test registration certificate Since the outbreak of the epidemic more than a year ago, Deepblue Medical has lived up to expectations. The series of COVID-19 detection reagents independently developed and produced have been widely recognized by authoritative medical and health institutions in various countries. Approvals from many European countries, such as the self-test certificate and the French family self-test white list, have brought great convenience to the European people's family-based self-test and reduced cross-infection caused by mutual contact. Deepblue SARS-CoV-2 home self-test antigen detection reagent was registered and certified in Italy and Portugal, which once again confirmed the excellent performance and good user experience of the Deepblue novel coronavirus home self-test antigen product. Anhui Deepblue Medical Technology Co., Ltd. adopts the methodology of colloidal gold immunochromatography to directly detect and capture the SARS-CoV-2 virus in human throat swabs, saliva, etc. The opera...

On August 23, 2021, Anhui Deepblue Medical's single-use non-inactivated virus sampling tube successfully passed the Indonesian registration. This successful Indonesian certification not only reflects the quality and craftsmanship of Anhui Deepblue Medical's non-inactivated virus sampling tube on a global scale Being recognized has also greatly improved the international brand influence of Anhui Deepblue Medical, and helped the company to enter a new journey with high-quality development. As we all know, as far as the test itself is concerned, in order to ensure the accuracy of the test results, one of the most important steps is to have accurate and qualified samples. In the face of the increasingly serious novel coronavirus, the novel coronavirus sampling tube is undoubtedly the most important tool and means to ensure that the samples are qualified and accurate, which means that there are higher requirements for the novel coronavirus collection tube. In addition to cooperating with the production of virus detection substances, the scientific researchers of Anhui Deepblue Medical also organized technical research and developed non-inactivated virus sampling tubes, focusing on solving the problems of sample collection, transportation and laboratory testing that may be caused by traditional products. In the link, it may cause the problem of secondary transmission of relevant medical staff and the surrounding environment. Anhui Deepblue medical non-inactivated virus sampling tube is used for sample collection, transportation and storage, etc., which is convenient for DNA/RNA extraction and the promotion and use of biological samples, viruses, etc. The sampling tube is mainly a virus maintenance liquid type preservation solution improved on the basis of the transport medium, and has good sealing performance and good stability. It can maintain the activity of the virus in vitro and the integrity of antigens and nucleic acids, protect the viral protein shell from being decomposed, and maintain the originality of the virus sample to a large extent. Refrigerated and transported at room temperature. In this special period, Anhui Deepblue Medical actively responded to the call of various departments, gave full play to its own technical advantages, and continued to provide corresponding material support for epidemic prevention and control, adhering to the concept of a global community with a shared future, and actively participating in the global fight against "epidemic" Go to help.

On July 22, COVID-19 antigen home self-test kit independently developed by Anhui Deepblue Medical Technology Co., Ltd. obtained the CE1434 certificate. This is after passing the British 3B stage test, the German BfarM special authorization, the Netherlands MINVWS special authorization, and the Czech home self-test certificate. Another major news that followed was another major innovation in DeepBlue’s anti-epidemic products. Anhui Deepblue Medical Technology Co., Ltd. is the first company in Anhui Province to obtain this certificate, and it is also one of the only ten companies in China. Since the outbreak of Coronavirus (COVID-19) worldwide in 2020, Deepblue Medical has integrated a large number of technical research and development forces, and independently developed 5 types of new crowns including antibodies, antigens, antigen + antibody and antigen + influenza A&B detection kits, and neutralizing antibodies. Pneumonia detection kits have completed product registration and obtained registration certificates in more than 60 countries overseas. Among them, Deepblue Coronavirus (COVID-19) antigen home self-test kit was broadcast on German TV. Deepblue medical has developed rapidly in the global IVD industry with its superb product technology and high-quality product quality, making the "Made in China, Deepblue Manufacturing" reputation in the international market. In the future, Deepblue Medical will continue to work hard to cooperate with all countries in the world with high-quality products, preferential prices, efficient production capacity, faster speed and better service.